嵌合抗原受体
免疫疗法
医学
临床疗效
疾病
重症监护医学
生物信息学
免疫学
生物
内科学
免疫系统
作者
Theano I. Panagopoulou,Qasim A. Rafiq
标识
DOI:10.1016/j.biotechadv.2019.06.010
摘要
T cells engineered to express a chimeric antigen receptor (CAR) have re-shaped the way hematological malignancies are treated. Despite the overwhelming early clinical success, CAR-T therapies are associated with severe side-effects, disease relapse and often exhibit limited efficacy. In this Review article we summarize the most recent biotechnological advances that have been developed to enhance the efficacy and specificity of CAR-T therapies, as well as to address the key challenges associated with them. We place particular emphasis on the most recent clinical data that indicate which CAR-T populations are the most relevant to clinical success, and indicate how the molecular structure of the CAR receptor can affect clinical outcome. Finally, we outline what we believe is the next generation of immunotherapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI